Cantor Fitzgerald reiterates Overweight rating on Metsera stock

Despite a recent 8.9% stock decline and a Q2 earnings miss of $0.66 per share, Metsera Inc. (NASDAQ:MTSR) maintains strong analyst support, with Cantor Fitzgerald reiterating an Overweight rating and Leerink Partners initiating Outperform. The optimism stems from Metsera's innovative oral GLP-1 pipeline, particularly MET-097o and MET-224o, which are in early development and offer competitive advantages like scalability and no food/water restrictions. Initial proof-of-concept data for these oral peptides is expected in late 2025, with significant catalysts anticipated over the next six months, suggesting potential upside as their success is not yet fully priced into the current $33.25 valuation.

Analysis

Despite a recent 8.9% stock decline and a second-quarter earnings miss with a loss of $0.66 per share against estimates of $0.63, Metsera Inc. (MTSR) maintains a strong bullish outlook from analysts. The core of this optimism lies in the company's early-stage oral GLP-1 pipeline, which is viewed as a significant potential value driver not yet priced into the current valuation of $33.25. Cantor Fitzgerald reiterated an Overweight rating, and Leerink Partners initiated coverage with an Outperform rating and a $77 price target, underscoring the perceived upside. The key assets, oral peptides MET-097o and MET-224o, offer potential competitive advantages such as scalability and no food or water restrictions. The market is anticipating initial proof-of-concept data for these treatments in late 2025, but the next six months are deemed pivotal, with multiple portfolio updates expected that could serve as significant short-term catalysts and provide clarity on the development pathway.

Key Decisions for Investors

• Consider the current stock price weakness as a potential entry point for a high-risk, high-reward position, given the significant disconnect between the current price and analyst targets of $50-$77.
• Closely monitor company communications over the next six months for pivotal updates on the injectable and oral peptide portfolio, as these will be key de-risking events ahead of the major proof-of-concept data expected in late 2025.
• Acknowledge the near-term volatility risk, evidenced by the recent earnings miss and stock decline, and size positions according to a risk tolerance appropriate for an early-stage biotechnology firm heavily dependent on future clinical trial outcomes.